High response rate using recombinant interferon-alpha in patients with newly diagnosed chronic myeloid leukemia

Bone Marrow Transplantation

Volumn 17, Issue SUPPL. 3, 1996, Pages

  Mahon, F X ^a   Faberes C ^a   Montastruc, M ^a   Si Mour, S ^a   Boiron, J M ^a   Marit, G ^a   Bilhou Nabera, C ^a   Cony Makhoul, P ^a   Pigneux, A ^a   Bernard, Ph ^a   Broustet, A ^a   Reiffers, J ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Chronic myeloid leukemia; Interferon alpha; Therapy

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

ADOLESCENT; ADULT; AGED; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; FEMALE; HEPATITIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PERICARDITIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG TOLERANCE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON TYPE I, RECOMBINANT; LEUKEMIA, MYELOID, CHRONIC-PHASE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 15844398782     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Fialkow PJ, Jacobson RJ, Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to granulocyte, platelet and monocyte/macrophage. Am J Med 1977; 63: 125-130.
2. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.
3. Shtivelman E, Lifshitz B, Gale RP, Cananii E. Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 1985; 315: 550-554.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myeloid leukemia in mice by P210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247: 824-830.
5. Malinge MC, Mahon FX, Daheron L et al. Quantitative determination of the hybrid bcr-abl mRNA in patients with chronic myelogenous leukemia under Interferon therapy. Br J Haematol 1992; 82: 701-707.
6. Goldman JM. Bone marrow transplantation for chronic myeloid leukemia. Hem Oncol 1987; 5: 265-279.
7. McGlave PB, Beatty P, Ash R, Hows JM. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728-1732.
8. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69: 1280-1288.
9. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med 1995; 122: 254-261.
10. Montastruc M, Mahon FX, Fabères C et al. Respose to recombinant interferon-alpha in patients with chronic myelogenous leukemia in a single center: results analysis of predictive factors. Leukemia 1995; 9: 1997-2002.
11. Reiffers J, Trouette R, Marit G et al. Autologous blood stem cell transplantation for chronic granulocytic leukemia in transformation: a report of 47 cases. Br J Haematol 1991; 77: 339-345.
12. Ozer H, George SL, Schiffer CA et al. Prolonged subcutaneous administration of recombinant a2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and leukemia group B study 8583. Blood 1993; 82: 2975-2984.
13. The Italian cooperative study group on chronic myeloid leukemia. Interferon-alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. New Engl J Med 1994; 330: 820-825.
14. Hehlmann R, Heimpel H, Hasford J et al. The German CML Study Group: randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994, 12: 4064-4077.
15. Allan NC, Richard SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working parties for therapeutic trials in adult leukemia. UK Medical Research Council randomised, multicentre trial of interferon-an1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
16. Ohnishi K, Ohno R, Tomonoga M et al. A randomized trial comparing Interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995; 86: 906-916.
17. Kumar L, Gulati SC. Alpha-interferon on chronic myelogenous leukaemia. Lancet 1995; 346: 984-986.
18. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-a are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 1994; 121: 736-744.
19. Hasford J, Baccarani M, Hehlmann R, Tura, S, Ansari H, Zuffa E. The Italian and German chronic myeloid leukemia trials interferon-a - a comparative analysis. Blood 1995; 86 (Suppl. 1): abst 1063.
20. Mahon FX, Montastruc M, Faberes C, Reiffers J. Predicting complete cytogenetic response in chronic myelogenous leukemia (CML) patients treated by recombinant interferon-alpha. Blood 1994; 84: 3592-3594.